Pr ecis: The robust antitumor properties of B-Raf kinase inhibitors appear to relate to an ability to correct immune escape, suggesting new uses for these drugs in cancer treatment through combination with active immunotherapies. Pr ecis: This study identifies independent risk factors for benign proliferative breast disease, suggesting that these factors directly influence the early stages of breast cancer development.
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Pr ecis: These findings define a microRNA that potently activates p53 and suppresses ribosome biogenesis, defining a novel core regulatory pathway in cell proliferation and survival. Pr ecis: This article defines a nontranscriptional function in DNA repair for the core cell-cycle regulatory transcription factor E2F1.
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B-Raf V600E inhibitors are potent at halting melanoma progression in patients harboring oncogenic B-Raf V600E mutation. Recent studies indicate that chemotherapies and other target treatments suppress tumor growth via a host immunity-dependent manner. Using a genetically modified mouse model of melanoma, it was found that diminished CD40L-and IFNg-mediated signaling contributed to the formation of immunosuppressive tumor microenvironment and that treatment with a Braf V600E inhibitor, PLX4720, could reinvigorate local immune function. Indeed, maximal effectiveness of PLX4720 was dependent on restoration of CD40L-and IFNg-mediated immune signals. This study illustrates that certain chemotherapies directed at the tumor rely on immune signaling pathways and that this has relevance for the design of combined treatments with immunotherapies. For details, see the article by Ho and colleagues on page 3205. To request permission to re-use all or part of this article, contact the AACR Publications Department at
